ESTRO 2024 - Abstract Book

S1084

Clinical - Gynaecology

ESTRO 2024

Conclusion:

SABR for oligometastasic ovarian cancer revealed excellent local control and a good toxicity profile. Furthermore, 66,67% of our patients were alive 12 months after treatment was delivered, which may lead to hypothesize that radiotherapy (combined with new systemic therapies) could have a main role to improve our patient’s outcomes, with no worsening of their quality of life. In our study, local control, progression-free survival and overall survival were comparable to current literature 3,4,5 . Further investigation would be needed to clarify the role of radiotherapy in ovarian cancer oligorecurrences.

Keywords: Ovarian cancer recurrences

References:

1. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020 Sep 1;38(25):2830-2838. doi: 10.1200/JCO.20.00818. Epub 2020 Jun 2. PMID: 32484754; PMCID: PMC7460150.